Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of Mantle Cell Lymphoma
Phase of Trial: Phase II
Latest Information Update: 14 Jun 2017
At a glance
- Drugs Ibrutinib (Primary) ; Rituximab
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- 30 May 2016 Status changed from active, no longer recruiting to recruiting.
- 25 May 2016 Status changed from not yet recruiting to active, no longer recruiting.
- 19 Feb 2016 New trial record